Furthermore, in HCC patients received postoperative anti-PD-1 therapy, the results showed that patients with HBV DNA < 1000 copy/mL had significantly better RFS and OS than those with HBV DNA ≥ 1000 copy/mL. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.